Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EXEL

Exelixis Inc

Nov 07 • 04:00PM ET

40.81

+0.01 0.02 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VBK VXF XBI XMHQ MDY IBB IJK

Scroll to Statements

Index	-	P/E	17.18	EPS (ttm)	2.38	Insider Own	3.18%	Shs Outstand	268.10M	Perf Week	5.53%
Market Cap	10.94B	Forward P/E	12.62	EPS next Y	3.23	Insider Trans	-5.08%	Shs Float	259.57M	Perf Month	5.81%
Enterprise Value	10.13B	PEG	0.52	EPS next Q	0.76	Inst Own	97.50%	Short Float	8.05%	Perf Quarter	9.09%
Income	677.90M	P/S	4.78	EPS this Y	65.14%	Inst Trans	1.21%	Short Ratio	7.82	Perf Half Y	12.83%
Sales	2.29B	P/B	5.06	EPS next Y	11.24%	ROA	23.44%	Short Interest	20.88M	Perf YTD	22.55%
Book/sh	8.06	P/C	11.07	EPS next 5Y	33.32%	ROE	30.56%	52W High	49.62 -17.75%	Perf Year	17.37%
Cash/sh	3.69	P/FCF	14.03	EPS past 3/5Y	34.91% 11.55%	ROIC	29.01%	52W Low	31.90 27.93%	Perf 3Y	139.92%
Dividend Est.	-	EV/EBITDA	11.92	Sales past 3/5Y	14.76% 17.51%	Gross Margin	96.63%	Volatility	4.83% 3.74%	Perf 5Y	98.01%
Dividend TTM	-	EV/Sales	4.43	EPS Y/Y TTM	54.33%	Oper. Margin	35.85%	ATR (14)	1.47	Perf 10Y	577.91%
Dividend Ex-Date	-	Quick Ratio	3.68	Sales Y/Y TTM	9.93%	Profit Margin	29.63%	RSI (14)	58.71	Recom	1.90
Dividend Gr. 3/5Y	- -	Current Ratio	3.75	EPS Q/Q	71.73%	SMA20	5.32%	Beta	0.40	Target Price	45.00
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	10.79%	SMA50	4.73%	Rel Volume	0.87	Prev Close	40.80
Employees	1147	LT Debt/Eq	0.08	Earnings	Nov 04 AMC	SMA200	4.76%	Avg Volume	2.67M	Price	40.81
IPO	Apr 11, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.87% 1.29%	Trades		Volume	2,321,314	Change	0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform	$48
Sep-19-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Initiated	Goldman	Buy	$47
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$45 → $50
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight	$60
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18

Show Previous Ratings

Nov-06-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November (Business Wire)
04:56AM	Company News for Nov 6, 2025 (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks) +6.52%
12:08AM	Exelixis Inc (EXEL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-25 06:30PM	Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:55PM	Loading…
05:55PM	Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:55PM	Exelixis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-28-25 12:24PM	Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners (Insider Monkey)
10:00AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:01AM	Merck kidney cancer drug succeeds in two large trials (BioPharma Dive)
Oct-27-25 12:10PM	Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Oct-21-25 04:05PM	Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (Business Wire)
12:54PM	Loading…
12:54PM	Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results (Insider Monkey)
09:32AM	Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls (The Fly)
Oct-20-25 05:01AM	Exelixis shares dip on colorectal cancer data (BioPharma Dive) -12.00%
02:30AM	Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet (Business Wire)
Oct-18-25 03:00AM	Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 (Business Wire)
Oct-14-25 07:30AM	The Ultimate Biotech Stock to Buy With $50 Right Now (Motley Fool)
Oct-09-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Oct-08-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-30-25 04:10AM	Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years (Motley Fool)
Sep-27-25 12:59AM	Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook (Insider Monkey)
Sep-26-25 10:47AM	Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50 (Insider Monkey)
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly)
Sep-08-25 05:00PM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Sep-06-25 01:13AM	Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D (Insider Monkey)
Sep-05-25 11:31AM	Exelixis, Inc. (EXEL): A Bull Case Theory (Insider Monkey)
05:47PM	Loading…
Aug-29-25 05:47PM	Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development (Business Wire)
01:42PM	Do Options Traders Know Something About Exelixis Stock We Don't? (Zacks)
04:51AM	Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial (Insider Monkey)
Aug-28-25 11:30AM	Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? (Zacks)
Aug-27-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September (Business Wire)
11:30AM	Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report? (Zacks)
Aug-26-25 09:31AM	Can Label Expansion of Cabometyx Fuel Further Growth for EXEL? (Zacks)
Aug-25-25 08:45AM	Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now? (Zacks)
Aug-19-25 09:33AM	Will EXEL's Share Repurchase Program Boost Value for Investors? (Zacks)
Aug-18-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-14-25 09:11AM	Exelixis Gains 15.6% YTD: How Should You Play the Stock? (Zacks)
Aug-13-25 08:52AM	Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? (Zacks)
Aug-05-25 09:10AM	Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? (Zacks)
Aug-04-25 09:15AM	Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock (Zacks)
Jul-31-25 11:43AM	Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View (Zacks)
Jul-30-25 12:45PM	Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
08:05AM	Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint (Insider Monkey)
Jul-29-25 09:34PM	2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL (Zacks) -16.78%
12:00PM	All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy (Zacks)
09:38AM	EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues (Zacks)
07:49AM	Exelixis fall over 12% after revenue miss, halts zanzalintinib trial (Investing.com)
06:17AM	These Stocks Are Moving the Most Today: UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More (Barrons.com)
05:22AM	Sarepta surges, Whirlpool sinks, and other early market movers (MarketWatch)
03:05AM	Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges (GuruFocus.com)
Jul-28-25 05:20PM	Exelixis (EXEL) Beats Q2 Earnings Estimates (Zacks)
04:16PM	Exelixis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
11:26AM	Morgan Stanley makes bold S&P 500 projection as U.S. dollar weakens (TheStreet)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
02:07AM	Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT (Insider Monkey)
Jul-24-25 05:04PM	Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Jul-23-25 11:00AM	Exelixis Gains Analyst Confidence as Cancer Studies Advances (Insider Monkey)
10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings (Zacks)
Jul-22-25 10:00AM	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-21-25 11:40AM	EXEL vs. ARGX: Which Stock Should Value Investors Buy Now? (Zacks)
10:00AM	Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-20-25 06:30AM	Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner (Motley Fool)
Jul-19-25 06:09AM	After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. (Motley Fool)
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:50AM	Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? (Zacks)
09:20AM	Tempus AI Raises 2025 Financial Outlook: What's Backing It? (Zacks)
Jul-14-25 04:05PM	Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 (Business Wire)
12:45PM	Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
08:15AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
Jul-07-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
09:22AM	Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? (Zacks)
Jul-04-25 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
07:45AM	2 Stocks to Buy With Less Than $50 (Motley Fool)
Jul-03-25 11:40AM	EXEL or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
08:11AM	What's Fueling Tempus AI's Explosive Sales Growth? (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
10:32AM	Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold (Zacks)
Jun-28-25 06:35AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
Jun-27-25 01:14PM	Incyte Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
08:48AM	3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns (Zacks)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eckhardt Sue Gail	Director	Jun 02 '25	Sale	42.74	18,838	805,140	21,380	Jun 04 07:57 PM
WYSZOMIERSKI JACK L	Director	Jun 03 '25	Sale	43.09	7,535	324,683	358,882	Jun 04 07:57 PM
JACK L WYSZOMIERSKI	Director	Jun 03 '25	Proposed Sale	43.09	7,535	324,658		Jun 03 04:04 PM
Eckhardt Sue Gail	Director	Jun 02 '25	Proposed Sale	43.54	18,838	820,206		Jun 02 04:12 PM
Haley Patrick J.	EVP, Commercial	May 20 '25	Sale	44.06	34,387	1,515,091	412,072	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Sale	44.29	4,544	201,254	32,470	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Proposed Sale	44.29	4,544	201,259		May 21 04:08 PM
PATRICK JOSEPH HALEY	Officer	May 20 '25	Proposed Sale	44.06	34,387	1,514,998		May 20 05:23 PM
POSTE GEORGE	Director	May 16 '25	Option Exercise	19.77	20,634	407,934	189,654	May 16 08:58 PM
POSTE GEORGE	Director	May 16 '25	Sale	45.99	20,634	948,958	169,020	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Option Exercise	18.80	100,000	1,880,000	1,067,842	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Sale	46.00	100,000	4,600,000	967,842	May 16 08:58 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Option Exercise	20.09	36,508	733,351	1,300,050	May 16 08:57 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Sale	44.35	36,508	1,619,130	1,279,416	May 16 08:57 PM
MORRISSEY MICHAEL	President and CEO	May 14 '25	Option Exercise	18.80	308,365	5,797,262	1,931,374	May 16 08:57 PM
Hessekiel Jeffrey	EVP & General Counsel	May 15 '25	Sale	46.18	25,000	1,154,500	693,396	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Option Exercise	18.80	116,383	2,188,000	562,842	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Sale	47.96	126,383	6,061,703	446,459	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 14 '25	Sale	42.68	10,000	426,800	491,164	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Option Exercise	21.75	40,000	870,000	538,169	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Sale	45.47	72,776	3,309,125	465,393	May 16 08:57 PM
AMY PETERSON	Officer	May 16 '25	Proposed Sale	46.26	72,776	3,366,618		May 16 04:11 PM
CHRISTOPHER J SENNER	Officer	May 16 '25	Proposed Sale	46.00	100,000	4,600,000		May 16 04:09 PM
GEORGE POSTE	Director	May 16 '25	Proposed Sale	45.99	20,634	948,958		May 16 04:09 PM
STELIOS PAPADOPOULOS	Director	May 15 '25	Proposed Sale	44.35	36,508	1,619,130		May 15 06:00 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	48.05	116,383	5,592,739		May 15 05:09 PM
JEFFREY J HESSEKIEL	Officer	May 15 '25	Proposed Sale	46.18	25,000	1,154,610		May 15 04:29 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	46.95	10,000	469,500		May 15 04:05 PM
PATRICK JOSEPH HALEY	Officer	May 14 '25	Proposed Sale	42.68	10,000	426,800		May 14 04:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	May 01 '25	Sale	39.00	1,508	58,812	693,181	May 05 07:12 PM
DANA T AFTAB	Officer	May 01 '25	Proposed Sale	39.00	1,508	58,812		May 01 04:02 PM
Haley Patrick J.	EVP, Commercial	Mar 03 '25	Sale	38.80	10,000	388,000	341,028	Mar 05 08:47 PM
PATRICK JOSEPH HALEY	Officer	Mar 03 '25	Proposed Sale	38.80	10,000	388,000		Mar 03 04:18 PM
Smith Julie	Director	Feb 27 '25	Option Exercise	20.19	54,514	1,100,494	65,292	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Option Exercise	19.77	19,294	381,442	30,072	Feb 28 08:35 PM
Smith Julie	Director	Feb 27 '25	Sale	38.13	54,514	2,078,619	10,778	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Sale	37.62	19,294	725,840	10,778	Feb 28 08:35 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Option Exercise	20.50	15,874	325,417	365,373	Feb 28 08:34 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Sale	37.80	8,768	331,430	356,605	Feb 28 08:34 PM
JACK L WYSZOMIERSKI	Director	Feb 28 '25	Proposed Sale	37.80	8,768	331,394		Feb 28 04:05 PM
Smith Julie	Director	Feb 27 '25	Proposed Sale	37.13	73,808	2,740,491		Feb 27 05:12 PM
Haley Patrick J.	EVP, Commercial	Feb 24 '25	Sale	36.98	52,636	1,946,479	303,310	Feb 26 08:01 PM
Oliver Bob	Director	Feb 25 '25	Option Exercise	19.28	15,147	292,034	52,161	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Sale	37.25	18,647	694,601	33,514	Feb 26 08:00 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 24 '25	Sale	36.75	26,987	991,772	511,908	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Option Exercise	18.80	29,314	551,103	808,921	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Sale	36.14	29,314	1,059,408	779,607	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Proposed Sale	37.25	18,647	694,601		Feb 25 05:05 PM
Haley Patrick J.	Officer	Feb 24 '25	Proposed Sale	36.84	52,636	1,939,213		Feb 24 06:02 PM
Aftab Dana	Officer	Feb 24 '25	Proposed Sale	36.75	26,987	991,772		Feb 24 05:55 PM
Senner Christopher J.	Officer	Feb 24 '25	Proposed Sale	36.14	29,314	1,059,370		Feb 24 03:34 PM
Beckerle Mary C	Director	Feb 14 '25	Option Exercise	23.24	8,354	194,147	42,616	Feb 19 08:32 PM
Beckerle Mary C	Director	Feb 14 '25	Sale	34.88	12,210	425,878	30,406	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Option Exercise	20.50	15,874	325,417	184,894	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Sale	34.74	15,874	551,463	169,020	Feb 19 08:32 PM
Freire Maria C	Director	Feb 14 '25	Option Exercise	21.52	44,114	949,521	135,121	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Sale	34.94	44,114	1,541,343	91,007	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Option Exercise	23.24	7,712	179,227	41,974	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Sale	35.02	11,568	405,111	30,406	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Proposed Sale	34.94	44,114	1,541,207		Feb 14 05:59 PM
Beckerle Mary C	Director	Feb 14 '25	Proposed Sale	34.88	12,210	425,865		Feb 14 05:40 PM
POSTE GEORGE	Director	Feb 14 '25	Proposed Sale	34.74	15,874	551,431		Feb 14 05:36 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Proposed Sale	34.37	11,568	397,592		Feb 14 04:20 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your FINVIZ experience